For many people with epilepsy, current medications do not fully control their seizures. Dr. Klitgaard and Dr. Erler, and their team at Neumirna Therapeutics is developing NMT.001, a new antisense oligneucleotide therapy for the treatment of drug-resistant epilepsy. Studies have shown that NMT.001 has the potential to reduce seizures, improve survival, and even stop seizures long-term. To bring this therapy to patients faster, this project aims to develop blood-based tests or biomarkers that can help doctors determine which patients will benefit most from the treatment and also help track how well the treatment is working. Results obtained from this project will be used advance NMT.001 toward clinical trials.
Latest from the community
